Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers

Elizabeth K Bancroft et al. BJU Int. 2024 Sep.
Free article

Abstract

Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2).

Subjects and methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge.

Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time.

Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

Keywords: BRCA1; BRCA2; genetic screening; prostate cancer; psychosocial; quality of life.

PubMed Disclaimer

References

    1. Cancer Research UK. Prostate cancer statistics. Available at: https://www.cancerresearchuk.org/health‐professional/cancer‐statistics/s.... Accessed January 2024.
    1. Kote‐Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young‐onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230–1234
    1. Leongamornlert D, Mahmud N, Tymrakiewicz M et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012; 106: 1697–1701
    1. Castro E, Goh C, Leongamornlert D et al. Effect of BRCA mutations on metastatic relapse and cause‐specific survival after radical treatment for localised prostate cancer. Eur Urol 2015; 68: 186–193
    1. Page EC, Bancroft EK, Brook MN et al. Interim results from the IMPACT study: evidence for prostate‐specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019; 76: 831–842

Publication types